Education
About Us
Working with TipRanks
Follow Us
Altamira Therapeutics Ltd. (CYTOF)
:CYTOF
Top Page
Altamira Therapeutics
(OTC:CYTOF)
Select Model
Select Model
Rating:25Underperform
Price Target:―
Altamira Therapeutics exhibits significant financial and operational challenges, typical of early-stage biotechnology firms, with notable weaknesses in revenue generation and cash flow management. Technical indicators denote a strong bearish trend, with the stock trading well below key moving averages and showing oversold conditions. The lack of valuation metrics and earnings call insights adds to the uncertainty, leading to a cautious and low overall stock score.
Altamira Therapeutics (CYTOF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$542.97K
Dividend YieldN/A
Average Volume (3M)8.43K
Price to Earnings (P/E)―
Beta (1Y)2.53
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees12
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.31
Shares Outstanding5,715,472
10 Day Avg. Volume4,665
30 Day Avg. Volume8,434
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap2.09
Enterprise Value/Revenue-3.22
Enterprise Value/Gross Profit-1.65
Enterprise Value/Ebitda0.56
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Altamira Therapeutics Business Overview & Revenue Model
Company DescriptionAuris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The firm focuses on the development of intranasal betahistine for the treatment of vertigo and for the prevention of antipsychotic-induced weight gain and somnolence. It also includes other programs under development such as Keyzilen, for the treatment of acute inner ear tinnitus; and Sonsuvi, for the treatment of acute inner ear hearing loss. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.
How the Company Makes MoneyAltamira Therapeutics primarily generates revenue through the development and commercialization of its RNA-based therapeutic products. The company may earn income from licensing agreements, partnerships, and collaborations with other pharmaceutical companies to co-develop or market its therapies. Additionally, Altamira could secure funding through government grants, research collaborations, and milestone payments tied to the successful progression of its drug candidates through clinical trials. As its products gain regulatory approval and enter the market, sales from these therapies would also contribute to the company's revenue streams. Strategic alliances and potential royalties from licensed technologies further enhance Altamira's earnings potential.
Altamira Therapeutics Earnings Call Summary
Earnings Call Date:Aug 29, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Apr 15, 2026
Earnings Call Sentiment Neutral
Altamira showed significant progress in its RNA delivery business with new partnerships and patent filings, while overcoming setbacks such as Nasdaq delisting and increased net loss. The strategy to involve private equity investors and spin-off RNA delivery activities indicates proactive steps for future growth.Q4-2024 Updates
Positive Updates
RNA Delivery Business Momentum
Altamira gained 2 new partners for its xPhore platform and demonstrated its versatility with circular RNA, opening new business opportunities.
New Collaborations
Added a new collaboration agreement with a company in the radiopharmaceutical sector, expanding opportunities in cancer treatment.
Bentrio Nasal Spray Market Expansion
Expecting marketing approval for Bentrio in Mainland China, and received a patent for its composition in the U.S., providing protection up to 2040.
Decreased Cash Used in Operations
Cash used in operations decreased from $12.8 million in 2023 to $6.1 million in 2024.
Patent Application for CycloPhore
Filed a provisional patent application for CycloPhore with the U.S. Patent Office, highlighting its potential for circular RNA.
Negative Updates
Nasdaq Delisting
Nasdaq delisted Altamira's common shares due to a minimum bid price issue, impacting funding from public markets.
Increased Net Loss
Net loss for 2024 was $8.5 million compared to $4.3 million in the previous year, although 2023 included a profit from discontinued operations.
Decreased Shareholders' Equity
Shareholders’ equity decreased from $7.7 million at year-end 2023 to $6.6 million at year-end 2024.
Company Guidance
During the Altamira Therapeutics' full-year 2024 financial results and business update call, the company provided several key metrics and strategic insights. The operating loss from continuing operations increased slightly from $6.6 million in 2023 to $6.9 million in 2024. Research and development expenses rose to $3.7 million from $3.4 million the previous year, whereas general and administrative expenses decreased to $3.2 million from $3.5 million. Notably, net finance expenses dropped significantly from $1.5 million to $0.8 million. The net loss for 2024 was reported at $8.5 million, with a cash usage reduction in operations from $12.8 million in 2023 to $6.1 million in 2024. Cash and cash equivalents increased to $1 million by year-end. The company anticipates a reduction in operating expenses following the partial spin-off of its RNA delivery subsidiary, ATAG, and seeks to fund future operations through existing cash, private equity, and strategic partnerships.Altamira Therapeutics Financial Statement Overview
Summary
Altamira Therapeutics is facing financial challenges typical of early-stage biotechnology companies, marked by negative earnings, operational inefficiencies, and cash flow difficulties. While there is an improvement in equity, the company continues to struggle with revenue generation and cash management. These factors suggest a high-risk profile with potential needs for operational restructuring or additional funding.Income Statement
Altamira Therapeutics has been experiencing declining revenue, with a significant revenue drop from 2020 to 2023. The company has consistently reported negative net income, resulting in poor net profit margins. EBIT and EBITDA margins are also negative, indicating operational inefficiencies and challenges in managing costs relative to revenue.10
Very Negative
Balance Sheet
The company has demonstrated significant improvement in equity from a negative position in 2022 to a positive value in 2023, which is a positive sign. However, the debt-to-equity ratio remains concerning due to high liabilities relative to equity in earlier years. The equity ratio remains weak, reflecting limited asset backing by equity.20
Very Negative
Cash Flow
Altamira Therapeutics has faced persistent negative free cash flow, indicating ongoing cash outflows exceeding cash inflows. Additionally, the operating cash flow to net income ratio is negative, suggesting that the company struggles to convert income into cash, which could affect liquidity.15
Very Negative
| Breakdown | TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -353.22K | 0.00 | 305.62K | 63.88K | 174.47K | -56.00K |
| Gross Profit | -691.22K | 0.00 | -1.14M | -2.18M | 174.47K | -56.00K |
| EBITDA | 2.02M | -1.35M | -17.64M | -6.72M | -5.26M | -7.24M |
| Net Income | -15.83M | -7.27M | -26.53M | -17.39M | -8.20M | -6.63M |
Balance Sheet | ||||||
| Total Assets | 6.20M | 7.69M | 6.30M | 18.84M | 20.80M | 9.23M |
| Cash, Cash Equivalents and Short-Term Investments | 49.57K | 617.41K | 15.39K | 984.19K | 11.26M | 1.38M |
| Total Debt | 3.47M | 99.66K | 6.33M | 575.74K | 523.92K | 0.00 |
| Total Liabilities | 8.03M | 1.24M | 14.62M | 6.13M | 4.03M | 3.19M |
| Stockholders Equity | -1.82M | 6.46M | -8.31M | 12.70M | 16.77M | 6.04M |
Cash Flow | ||||||
| Free Cash Flow | -10.81M | -11.51M | -10.83M | -17.00M | -7.16M | -11.41M |
| Operating Cash Flow | -10.81M | -11.51M | -8.68M | -13.67M | -4.84M | -8.39M |
| Investing Cash Flow | -608.03K | 1.44M | -2.14M | -3.51M | -2.31M | -3.00M |
| Financing Cash Flow | 10.99M | 10.62M | 9.83M | 6.61M | 16.96M | 7.38M |
Altamira Therapeutics Technical Analysis
Negative
0.10
Price Trends
0.07
Positive
0.08
Positive
0.09
Negative
Market Momentum
<0.01
Negative
49.18
Neutral
77.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYTOF, the sentiment is Negative. The current price of 0.1 is above the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.07, and above the 200-day MA of 0.09, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 49.18 is Neutral, neither overbought nor oversold. The STOCH value of 77.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CYTOF.
Altamira Therapeutics Risk Analysis
Altamira Therapeutics disclosed 41 risk factors in its most recent earnings report. Altamira Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Altamira Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $1.19M | 0.29 | ― | ― | 306.41% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $4.21M | -0.11 | -60.37% | ― | -100.00% | 86.75% | |
30 Underperform | $3.86M | -0.08 | -660.37% | ― | ― | 74.27% | |
29 Underperform | $5.32M | -0.05 | ― | ― | -100.00% | 85.99% | |
25 Underperform | $542.97K | ― | -108.79% | ― | ― | ― |
* Healthcare Sector Average
CYTOF
Altamira Therapeutics
0.10
-0.41
-80.39%
BDRX
Biodexa Pharmaceuticals
6.80
-56.30
-89.22%
QCLS
Q/C Technologies
4.19
-163.32
-97.50%
SLRX
Salarius Pharmaceuticals
3.76
-21.29
-84.99%
SCNI
Scinai Immunotherapeutics
1.46
-1.99
-57.68%
OGEN
Oragenics
1.28
-8.16
-86.44%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.